Search Results for "Rituximab Patent"

02:39 EDT 7th May 2015 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rit...

Biosimilars of rituximab

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseas...

Anxiety Not Affected by Coping Style in Patients Receiving Rituximab

No difference in anxiety was found among patients with non-Hodgkin lymphoma who were assigned to maintenance rituximab compared with those patients who were assigned to rituximab re-treatment upon dis...

Current Role of Rituximab in Systemic Lupus (CME/CE)

(MedPage Today) -- A review of studies on the effectiveness of rituximab in treating SLE

Clinical trials: Rituximab for maintenance of remission in AAV

Maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) should reduce rates of relapse with minimal toxicity. The MAINRITSAN trial—the first randomized controlled tri...

Is Rituximab Ready for Prime Time in SSc? (CME/CE)

(MedPage Today) -- Experts: new data support rituximab for reducing lung fibrosis in systemic sclerosis.

Rituximab for ANCA-Associated Vasculitides

After cyclophosphamide induction, three patients (5%) experienced major relapse on rituximab vs 17 (29%) on azathioprine in an unblinded trial. Medscape Medical News

Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome

A new trial provides further evidence that rituximab treatment can reduce the risk of relapse in children with steroid-dependent idiopathic nephrotic syndrome. Addition of a single infusion of rituxim...

Matching PubMed Articles

Patent highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent Highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent Highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis.

To the Editor: In their article on the Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trial, Guillevin and colleagues (Nov. 6 issue)(1) report that rituxi...

Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis.

To the Editor: In their article on the Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trial, Guillevin and colleagues (Nov. 6 issue)(1) report that rituxi...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement